Article information
Abstract
Aminobisphosphonates are drugs that have been used successfully in the treatment of osteoporosis for more than 20 years. Although main registry studies found a scarcity of relevant adverse events, in recent years and as a result of pharmacovigilance, different complications have been reported, some potentially serious. This has raised questions on the safety of these drugs, especially in high doses, like those used in oncology and long-term treatment, as needed in patients with osteoporosis. In this review, based on the analysis of relevant scientific evidence from clinical trials, case series, cohort studies and databases published to date, we summarize the clinical and epidemiological characteristics of the adverse effects of these drugs.
Keywords:
Osteoporosis
Aminobisphosphonates
Adverse effects
Resumen
Los aminobisfosfonatos son fármacos que han sido utilizados con éxito en el tratamiento de la osteoporosis desde hace más de 20 años. Aunque en los estudios principales realizados para obtener la aprobación de su comercialización no se registraron efectos adversos relevantes, en los últimos años, y como resultado de la farmacovigilancia, se ha comunicado de manera irregular una serie de complicaciones, algunas potencialmente graves, que han puesto en duda la seguridad de estos fármacos, sobre todo en dosis elevadas como las que se utilizan en oncología y en tratamientos de larga duración, como los que se emplean en la osteoporosis. En la presente revisión, basada en el análisis de las pruebas científicas más relevantes procedentes de los ensayos clínicos, series de casos, estudios de cohortes y bases de datos publicados hasta el momento, se resumen las características clínicas y epidemiológicas de los efectos adversos de los bisfosfonatos.
Palabras clave:
Osteoporosis
Bisfosfonatos
Efectos adversos
Full text is only aviable in PDF
References
[1.]
L. Arboleya.
Bisfosfonatos.
Manual de enfermedades óseas de la Sociedad Española de Reumatología, 2nd ed, pp. 319-330
[2.]
P. Miller.
Bisphosphonates.
Osteoporosis, 3rd ed, pp. 1725-1742
[3.]
C.A. Brauer, M. Coca-Perraillon, D.M. Cutler, A.B. Rosen.
Incidence mortality of hip fractures in the United States.
JAMA, 302 (2009), pp. 1573-1579
[4.]
B. Abrahamsen, P. Vestergaard.
Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997-2006.
Osteoporosis Int, 21 (2010), pp. 373-380
[5.]
A.J. Roelofs, K. Thompson, S. Gordon, M.J. Rogers.
Molecular mechanisms of action of bisphosphonates: current status.
Clin Cancer Res, 12 (2006), pp. 6222-6230
[6.]
R.S. Weinstein, P.K. Roberston, S.C. Manolagas.
Giant osteoclast formation and long-term oral bisphosphonate therapy.
N Engl J Med, 360 (2009), pp. 53-62
[7.]
P.C. De Groen, D.F. Lubbe, L.J. Hirsch, A. Daifotis, W. Stephenson, D. Freedholm, et al.
Esophagitis associated with the use of alendronate.
N Engl J Med, 335 (1996), pp. 1016-1021
[8.]
Ficha técnica de Fosamax. Available from: http://www.msd.es/content/hcp/productos/ft/ft_fosamax_10_es.pdf.
[9.]
P. Vestergaard, K. Schwartz, E.M. Pinholt, L. Rejnmark, L. Mosekilde.
Gastric and esophagus events before and during treatment of osteoporosis.
Calcif Tissue Int, 86 (2010), pp. 110-115
[10.]
R.S. Bobba, K. Beattie, B. Parkinson, D. Kumbhare, J.D. Adachi.
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Drug Saf, 29 (2006), pp. 1133-1152
[11.]
S.M. Cadarette, J.N. Katz, M.A. Brookhart, T. Sturmer, M.R. Stedman, R. Levin, et al.
Comparative gastrointestinal safety of weekly oral bisphosphonates.
Osteoporos Int, 20 (2009), pp. 1735-1747
[12.]
D.K. Wysowski.
Reports of esophageal cancer with oral bisphosphonate use.
N Engl J Med, 360 (2009), pp. 89-90
[13.]
B. Abrahamsen, P. Eiken, R. Eastell.
More on reports of esophageal cancer with oral bisphosphonate use.
N Engl J Med, 360 (2009), pp. 1789
[14.]
D.H. Solomon, A. Patrick, M.A. Brookhart.
More on reports of esophageal cancer with oral bisphosphonate use.
N Engl J Med, 360 (2009), pp. 1790-1792
[15.]
F. De Vries, A.L. Cooper, S.M. Cockle, T.P. Van Staa, C. Cooper.
Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates.
Osteoporos Int, 20 (2009), pp. 1989-1998
[16.]
D.D. French, C.E. Margo.
Postmarketing surveillance of uveitis and scleritis with bisphosphonates among a national veteran cohort.
Retina, 28 (2008), pp. 889-893
[17.]
B. Aurich-Barrera, L. Wilton, S. Harris, S.W. Shakir.
Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England.
Drug Safety, 29 (2006), pp. 151-160
[18.]
A.R. Malik, S.H. Campbell, N.M.G. Toma.
Bilateral acute anterior uveitis after alendronate.
Br J Ophthalmol, 86 (2002), pp. 1443
[19.]
F.W. Fraunfelder, F.T. Fraunfelder, B. Jensvold.
Scleritis and other ocular side effects associated with pamidronate disodium.
Am J Ophthalmol, 135 (2003), pp. 219-222
[20.]
N.S. El Saghir, Z.K. Otrock, J.H. Bleik.
Unilateral anterior uveitis complicating zoledronic acid therapy in breast cancer.
BMC Cancer, 5 (2005), pp. 156
[21.]
S. Leung, B.H. Ashar, R.G. Miller.
Bisphosphonate-associated scleritis: a case report and review.
South Med J, 98 (2005), pp. 733-735
[22.]
D. Benderson, Karakunnel, S. Kathuria, A. Badros.
Scleritis complicating zoledronic acid infusion.
Clin Lymphoma Myeloma, 7 (2006), pp. 145-147
[23.]
S. Kilickap, Y. Ozdamar, M.K. Altundag, O. Dizdar.
A case report: zoledronic acid induced uveitis.
Med Oncol, 25 (2008), pp. 238-240
[24.]
K.F. Tabbara.
Nodular scleritis following alendronate therapy.
Ocul Immunol Inflamm, 16 (2008), pp. 99-101
[25.]
A. Colucci, G. Modorati, E. Miserocchi, F. Di Matteo, P. Rama.
Anterior uveitis complicating zoledronic acid infusion.
Ocul Immunol Inflamm, 17 (2009), pp. 267-268
[26.]
J. Muñoz Ortego, J. Carbonell Abello.
Ocular toxicity, bisphosphonate and Paget disease.
Med Clin (Barc), 133 (2009), pp. 198
[27.]
Y.L. Tan, J. Sims, S.P. Chee.
Bilateral uveitis secondary to bisphosphonate therapy.
Ophthalmologica, 223 (2009), pp. 215-216
[29.]
F. Procianoy, E. Procianoy.
Orbital inflammatory disease secondary to a single-dose administration of zoledronic acid for treatment of postmenopausal osteoporosis.
Osteoporos Int, 21 (2010), pp. 1057-1058
[30.]
C.A. Dasanu, D.T. Alexandrescu.
Acute retinal pigment epithelial detachment secondary to pamidronate administration.
J Oncol Pharm Pract, 15 (2009), pp. 119-121
[31.]
V. Raja, P. Sandanshiv, M. Neugebauer.
Risedronate induced transient ocular myasthenia.
J Postgrad Med, 53 (2007), pp. 274-275
[32.]
A. Seth, D.P. Anderson, D.A. Albiani, J.J. Barton.
Orbital inflammation and optic neuropathy with zoledronic acid for metastatic prostate cancer.
Can J Ophthalmol, 44 (2009), pp. 467-468
[33.]
N. Miura, N. Mizuno, R. Aoyama.
Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with segmental glomerulosclerosis.
Clin Exp Nephrol, 13 (2009), pp. 85-88
[34.]
L.S. Rosen, D. Gordon, M. Kaminski, A. Howell, A. Belch, J. Mackey, et al.
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Cancer, 98 (2003), pp. 1735-1744
[35.]
J.T. Chang, L. Green, J. Beitz.
Renal failure with the use of zoledronic acid.
N Engl J Med, 349 (2003), pp. 1676-1679
[36.]
J. Balla.
The issue of renal safety of zoledronic acid from a nephrologist's point of view.
Oncologist, 10 (2005), pp. 306-308
[37.]
M.A. Perazella, G.S. Markowitz.
Bisphosphonate nephrotoxicity.
Kidney Int, 74 (2008), pp. 1385-1393
[38.]
J.J. Body.
The risk of cumulative renal effects of intravenous bisphosphonates.
Support Cancer Ther, 3 (2006), pp. 77-83
[39.]
S.K. Jassal, D. Von Muhlen, E. Barrett-Connor.
Measures of renal function BMD, bone loss, and osteoporotic fracture in older adults: the Rancho Bernardo Study.
J Bone Min Res, 22 (2007), pp. 203-210
[40.]
S. Chennuru, J. Koduri, M.A. Bauman.
Risk factors for symtomatic hypocalcemia complicating treatment with zoledronic acid.
Intern Med J, 38 (2008), pp. 635-637
[41.]
M. Zuradelli, G. Masci, G. Biancofiore, G. Gullo, M. Scorsetti, P. Navarria, et al.
High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid.
Oncologist, 14 (2009), pp. 548-556
[42.]
D.H. Schussheim, T.P. Jacobs, S.J. Silverberg.
Hypocalcemia associated with alendronate.
Ann Intern Med, 130 (1999), pp. 329
[43.]
G. Liamis, H.J. Milionis, M. Elisaf.
A review of drug-induced hypocalcemia.
J Bone Miner Metab, 27 (2009), pp. 635-642
[44.]
N.M. Maalouf, H.J. Heller, C.V. Odvina, P.J. Kim, K. Sakhaee.
Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature.
Endocr Pract, 12 (2006), pp. 48-53
[45.]
S. Adami, A.K. Bhalla, R. Dorizzi, F. Montesanti, S. Rosini, G. Salvagno, et al.
The acute-phase response after bisphosphonate administration.
Calcif Tissue Int, 41 (1987), pp. 326-331
[46.]
K. Olson, C. Van Poznak.
Significance and impact of bisphosphonate-induced acute phase responses.
J Oncol Pharm Pract, 13 (2007), pp. 223-229
[47.]
R. Casseti, A. Martino.
The plasticity of gammadelta T Cells: innate immunity, antigen presentation and new immunotherapy.
Cell Mol Immunol, 5 (2008), pp. 161-170
[48.]
Y. Tanaka, C.T. Morita, Y. Tanaka, E. Nieves, M.B. Brenner, B.R. Bloom.
Natural and synthetic non-peptide antigens recognized by human gamma delta T cells.
Nature, 375 (1995), pp. 155-158
[49.]
H.J. Gober, M. Kistowska, L. Angman, P. Jeno, L. Mori, G. De Libero, T. Human.
cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells.
J Exp Med, 197 (2003), pp. 163-168
[50.]
S. Galluzzo, D. Santini, B. Vincenzi, N. Caccamo, F. Meraviglia, A. Salerno, et al.
Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity.
Expert Opin Ther Targets, 7 (2007), pp. 941-954
[51.]
K. Thompson, M.J. Rogers.
Statins prevent bisphosphonate-induced gamma-delta-T-cell proliferation and activation in vitro.
J Bone Miner Res, 2 (2004), pp. 278-288
[52.]
R.E. Hewitt, A. Lissina, A.E. Green, E.S. Slay, D.A. Price, A.K. Sewell.
The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gamma/delta T cells in response to aminobisphosphonates is inhibited by statins.
Clin Exp Immunol, 139 (2005), pp. 101-111
[53.]
T. Srivastava, C.J. Haney, U.S. Alon.
Atorvastatin may have no effect on acute phase reaction in children following intravenous bisphosphonate infusion.
J Bone Min Res, 24 (2009), pp. 334-337
[54.]
F. Bertoldo, S. Pancheri, S. Zenari, S. Boldini, B. Giovanazzi, M. Zanatta, et al.
Serum 25(OH)D levels modulate the Acute Phase Response associated to the first nitrogen containing bisphosphonate infusion.
J Bone Miner Res, 14 (2009), pp. 1-33
[55.]
D.M. Black, P.D. Delmas, R. Eastell, I.R. Reid, S. Boonen, J.A. Cauley, et al.
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
N Engl J Med, 356 (2007), pp. 1809-1822
[56.]
S.R. Cummings, A.V. Schwartz, D.M. Black.
Alendronate and atrial fibrillation.
N End J Med, 356 (2007), pp. 1895-1896
[57.]
H.T. Sørensen, S. Christensen, F. Mehnert, L. Pedersen, R.D. Chapurlat, S.R. Cummings, et al.
Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study.
BMJ, 336 (2008), pp. 813-816
[58.]
S.R. Heckbert, G. Li, S.R. Cummings, N.L. Smith, B.M. Psaty.
Use of alendronate and risk of incident atrial fibrillation in women.
Arch Int Med, 168 (2008), pp. 826-831
[59.]
K.W. Lyles, C.S. Colón-Emeric, J.S. Magaziner, J.D. Adachi, C.F. Pieper, C. Mautalen, et al.
Zoledronic acid and clinical fractures and mortality after hip fracture.
N Engl J Med, 357 (2007), pp. 1799-1809
[61.]
D.K. Wysowski, J.T. Chang.
Alendronate and risedronate: reports of severe bone, joint, and muscle pain.
Arch Intern Med., 165 (2005), pp. 346-347
[62.]
O. Bock, H. Boerst, F.E. Thomasius, C. Degner, M. Stephan-Oelkers, S.M. Valentine, et al.
Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention.
J Musculoskelet Neuronal Interact, 7 (2007), pp. 144-148
[63.]
US Food and Drug Administration. FDA MedWatch Safety Alert Web site. Information for healthcare professionals: bisphosphonates. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm101551.htm. Published January 7, 2008.
[64.]
L. Caplan, C.B. Pittman, A.L. Zeringue, J.F. Scherrer, K.R. Wehmeier, F.E. Cunningham, et al.
An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy.
May Clin Proc, 85 (2010), pp. 341-348
[65.]
O.U. Yemisci, S.A. Yalbuzdag, M. Karatas.
Risedronate-induced arthritis.
J Clin Rheumatol, 16 (2010), pp. 168-169
[66.]
D.P. Gwynne Jones, R.L. Savage, J. Highton.
Alendronate-induced synovitis.
J Rheumatol, 35 (2008), pp. 537-538
[67.]
L. Frederiksen, P. Junker, K.T. Brixen.
Persistent polyarticular synovitis after treatment with alendronate.
Ugeskr Laeger, 169 (2007), pp. 1583-1584
[68.]
C.V. Odvina, J.E. Zerwekh, E.S. Rao, N. Maalouf, F.A. Gottschalk, C.Y.C. Pak.
Severely suppressed bone turnover: a potential complication of alendronate therapy.
J Clin Endocrinol, 90 (2005), pp. 1294-1301
[69.]
A.M. Parfitt.
Renal bone disease: a new conceptual framework for interpretation of bone histomorphometry.
Curr Opin Nephrol Hypertens, 12 (2003), pp. 387-408
[70.]
M. Visekruna, D. Wilson, F.E. McKienan.
Severely suppressed bone turnover and atypical skeletal fragility.
J Clin Endocrinol Metab, 93 (2008), pp. 2948-2952
[71.]
S.K. Gosh, K.Y. Yang, J.S. Koh, M.K. Wong, S.Y. Chua, D.T. Chua, et al.
Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.
J Bone Joint Surg (Br), 89 (2007), pp. 349-353
[72.]
A.S. Neviaser, J.M. Lane, B.A. Lenart, F. Edobor-Osula, D.G. Lorich.
Low-energy femoral shaft fractures associated with alendronate use.
J Orthop Trauma, 22 (2008), pp. 346-350
[73.]
M.P. Somford, F.W. Draijer, B.J. Thomassen, P.M. Chavassieux, G. Boivin, S.E. Papapoulos.
Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility.
J Bone Miner Res, 24 (2009), pp. 1736-1740
[74.]
J.K. Lee.
Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium.
Int J Rheum Dis, 12 (2009), pp. 149-154
[75.]
E.B. Kwek, S.K. Gosh, J.S. Koh, M.A. Png, T.S. Howe.
An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?.
Injury, 39 (2008), pp. 224-231
[76.]
J.S. Koh, S.K. Goh, M.A. Png, E.B. Kwek, T.S. Howe.
Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture?.
J Orthop Trauma, 24 (2010), pp. 75-81
[77.]
D.M. Black, M.P. Kelly, H.K. Genant, L. Palermo, R. Eastell, C. Bucci-Rechtweg, et al.
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.
N Engl J Med, 362 (2010), pp. 1761-1771
[78.]
B.J. Edwards, M. Gounder, J.M. McKoy.
Pharmacovigilance and reporting oversight in US-FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.
Lancet Oncol, 9 (2008), pp. 1166-1172
[79.]
R.E. Marx.
Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
J Oral Maxillofac Surg, 61 (2003), pp. 1238-1239
[80.]
S.L. Ruggiero, B. Mehrotra, T.J. Rosenberg, S.L. Engroff.
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.
J Oral Maxillofac Surg, 62 (2004), pp. 527-534
[81.]
A. Bamias, E. Kastritis, C. Bamia, L.A. Moulopoulos, I. Melakopoulos, G. Bozas, et al.
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
J Clin Oncol, 23 (2005), pp. 8580-8587
[82.]
S.B. Woo, J.W. Hellstein, J.R. Kalmar.
Narrative review: bisphosphonates and osteonecrosis of the jaws.
Ann Intern Med, 144 (2006), pp. 753-761
[83.]
S. Khosla, D. Burr, J. Cauley, D.W. Dempster, P.R. Ebeling, D. Felsenberg, et al.
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.
J Bone Min Res, 22 (2007), pp. 1479-1491
[84.]
B. Abrahamsen.
Adverse effects of bisphosphonates.
Calcif Tissue Int, 86 (2010), pp. 421-435
[85.]
Y. Morag, M. Morag-Hezroni, D.A. Jamadar, B.B. Ward, J.A. Jacobson, S.R. Zwetchkenbaum, et al.
Bisphosphonate related osteonecrosis of the jaw: a pictorial review.
Radiographics, 29 (2009), pp. 1971-1984
[86.]
S. Hoefert, I. Schmitz, A. Tannapfel, H. Eufinger.
Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
Clin Oral Investig, 14 (2010), pp. 271-284
[87.]
D.B. Burr, M.R. Allen.
Mandibular necrosis in beagle dogs treated with bisphosphonates.
Orthod Craniofac Res, 12 (2009), pp. 221-228
[88.]
A.A. Reszka, J. Halasy-Nagy, G.A. Rodan.
Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation.
Mol Pharmacol, 59 (2001), pp. 193-202
[89.]
J.B. Aragon-Ching, Y.M. Ning, C.C. Chen, L. Latham, J.P. Guadagnini, J.L. Gulley, et al.
Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
Cancer Invest, 27 (2009), pp. 221-226
[90.]
Y. Bi, Y. Gao, D. Ehirchiou, C. Cao, T. Kikuiri, A. Le, et al.
Bisphosphonates cause Osteonecrosis of the jaw-like disease in mice.
Am J Pathol, 177 (2010), pp. 280-290
[91.]
Nota informativa, 2009/10., Nota informativa 2009/10. Recomendaciones para la prevención de la osteonecrosis del maxilar asociada al tratamiento con bisfosfonatos [accessed 2010 May 4]. Agencia Española de Medicamentos y Productos Sanitarios. Available from: http://www.aemps.es/actividad/alertas/usoHumano/seguridad/NI_2009-10_bisfosfonatos.htm
[92.]
R.E. Marx, J.E. Cillo, J.J. Ulloa.
Oral bisphosphonateinduced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
J Oral Maxillofac Surg, 65 (2007), pp. 2397-2410
[93.]
R. Kunchur, A. Need, T. Hughes, A. Goss.
Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
J Oral Maxillofac Surg, 67 (2009), pp. 1167-1173
[94.]
S. Baim, P.D. Miller.
Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw.
J Bone Miner Res, 24 (2009), pp. 561-574
[95.]
A.O. Hoff, B.B. Toth, K. Altundag, M.M. Johnson, C.L. Warneke, M. Hu, et al.
Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.
J Bone Miner Res, 23 (2008), pp. 826-836
[96.]
T. Boonyapakorn, I. Schirmer, P.A. Reichart, I. Sturm, G. Massenkeil.
Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.
Oral Oncol, 44 (2008), pp. 857-869
[97.]
K. Vahtsevanos, A. Kyrgidis, E. Verrou, E. Katodritou, S. Triaridis, C.G. Andreadis, et al.
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
J Clin Oncol, 27 (2009), pp. 5356-5362
[98.]
C. Walter, B. Al-Nawas, A. Du Bois, L. Buch, P. Harter, K.A. Grötz.
Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
Cancer, 115 (2009), pp. 1631-1637
[99.]
J.B. Aragon-Ching, Y.M. Ning, C.C. Chen, L. Latham, J.P. Guadagnini, J.L. Gulley, et al.
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
Cancer Invest, 2 (2009), pp. 221-226
[100.]
V. Guarneri, D. Miles, N. Robert, V. Diéras, J. Glaspy, I. Smith, et al.
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Breast Cancer Res Treat, 122 (2010), pp. 181-188
[101.]
T.I. Jung, F. Hoffmann, G. Glaeske, D. Felsenberg.
Disease specific risk for an osteonecrosis of the jaw under bisphosphonate therapy.
J Cancer Res Clin Oncol, 136 (2010), pp. 363-370
[102.]
J.C. Lo, F.S. O’Ryan, N.P. Gordon, J. Yang, R.L. Hui, D. Martin, et al.
Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.
J Oral Maxillofac Surg, 68 (2010), pp. 243-253
[103.]
T. Mavrokokki, A. Cheng, B. Stein, A. Goss.
Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
J Oral Maxillofac Surg, 65 (2007), pp. 415-423
[104.]
P.P. Sedghizadeh, K. Stanley, M. Caligiuri, S. Hofkes, B. Lowry, C.F. Shuler.
Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry.
J Am Dent Assoc, 140 (2009), pp. 61-66
[105.]
N. Patlas, G. Golomb, P. Yaffe, T. Pinto, E. Breuer, A. Ornoy.
Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats.
Teratology, 60 (1999), pp. 68-73
[106.]
A.R. Rutgers-Verhage, T.W. De Vries, M.J.L. Torringa.
No effects of bisphosphonates on the human fetus.
Birth Defects Res, 67 (2003), pp. 203-204
[107.]
K. Siminoski, A.A. Fitzgerald, G. Flesch, M.S. Gross.
Intravenous pamidronate for treatment of reflex sympathetic dystrophy during breast feeding.
J Bone Miner Res, 15 (2000), pp. 2052-2055
[108.]
M. Ostenesen, M. Khamashta, M. Locksin, A. Parke, A. Brucato, H. Carp, et al.
Anti-inflammatory and immunosuppresive drugs and reproduction.
Arthritis Res Ther, 8 (2006), pp. 209-228
[109.]
P. Musette, M.L. Brandi, P. Cacoub, J.M. Kaufman, R. Rizzoli, J.Y. Reginster.
Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity.
Osteoporos Int, 21 (2010), pp. 723-732
[110.]
B. Yanik, C. Turkay, H. Atalar.
Hepatotoxicity induced by alendronate therapy.
Osteoporos Int, 18 (2007), pp. 829-831
[111.]
A. Halabe, B.M. Lifschitz, J. Azuri.
Liver damage due to alendronate.
N Engl J Med, 343 (2000), pp. 365-366
[112.]
B.A. Barrera, L. Wilton, S. Harris, S.A. Shakir.
Prescription event monitoring study on 13,164 patients prescribed risedronate in primary care in England.
Osteoporos Int, 16 (2005), pp. 1989-1998
[113.]
P.N. Biswas, L.V. Wilton, S.A. Shakir.
Pharmacovigilance study of alendronate in England.
Osteoporos Int, 14 (2003), pp. 507-514
Copyright © 2011. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
